Duquesne University, Flag Therapeutics announce cancer-drug licensing pact

Share with others:


Print Email Read Later

Duquesne University and Flag Therapeutics Inc. of Raleigh, N.C., have agreed to a worldwide licensing agreement for two classes of water-soluble cancer drugs.

According to a statement, the two small-molecule compounds will be the first to combine the dual action of two major classes of cancer drugs into a single molecule.

One class of drugs circumvents naturally-occurring mechanisms of drug resistance while the other works to interrupt cell multiplication. By combining the two, the cancer cells will be targeted when they are most vulnerable while avoiding harm to healthy cells.

Heading the project at Duquesne is cancer researcher Aleem Gangiee.


Steve Twedt: stwedt@post-gazette.com or 412-263-1963.

Join the conversation:

Commenting policy | How to report abuse
To report inappropriate comments, abuse and/or repeat offenders, please send an email to socialmedia@post-gazette.com and include a link to the article and a copy of the comment. Your report will be reviewed in a timely manner. Thank you.
Commenting policy | How to report abuse

Advertisement
Advertisement
Advertisement

You have 2 remaining free articles this month

Try unlimited digital access

If you are an existing subscriber,
link your account for free access. Start here

You’ve reached the limit of free articles this month.

To continue unlimited reading

If you are an existing subscriber,
link your account for free access. Start here